Optimizing risk factors to guide COST‐effective use of palivizumab in KOREAN infants
Pediatrics International · 2025-01 · 67 (1)
DOI: 10.1111/ped.70021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 11.04.2025. Verfasst von Ji-Man Kang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Palivizumab, Respiratory Syncytial Virus Infections, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Korean infants born at 32–35 weeks gestational age (wGA) receive palivizumab prophylaxis to prevent respiratory syncytial virus hospitalization (RSVH) if they are born during the RSV season and have a sibling. The aim of this study was to evaluate the impact of using the International Risk Scoring Tool (IRST) to target prophylaxis in Korea.
Methods
The IRST includes 3 risk factors: birth 3 months before to 2 months after the RSV season starts; smokers in the household and/or smoking while pregnant; and, siblings/daycare. First, the accuracy of the Korean guidelines to predict RSVH was compared to that of the IRST using a historic dataset of 13,475 infants born 32–35 wGA. Second, a published cost‐utility model was adapted using Korean‐specific parameters for costs (2022) and resource use to assess the cost‐effectiveness of palivizumab versus no prophylaxis guided either by the Korean guidelines or the IRST.
Results
Using the Korean guidelines identified 26.9% of RSVHs, with an area under the receiver operating characteristic curve of 0.512. The corresponding results for infants assessed at moderate‐ to high‐risk by the IRST were 85.1% and 0.773, respectively. The incremental cost per quality‐adjusted life year (QALY) for prophylaxis versus no prophylaxis was ₩29,674,102 (USD22,977) using the Korean guidelines, with a 67.0% probability for cost‐effectiveness against a willingness‐to‐pay threshold of ₩41,655,203 (USD32,255). For the IRST, it was ₩26,265,142 (USD20,338)/QALY and 70.8% probability.
Conclusions
Adoption of the IRST in Korea would provide greater protection of the most vulnerable infants born 32–35 wGA against RSVH whilst improving cost‐effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, South Korea.
- Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea.
- Hospital Clinic, Barcelona, Spain.
- McMaster University, Hamilton, Ontario, Canada.
- Violicom Medical Limited, Aldermaston, UK.
- St Joseph's Healthcare, Hamilton, Ontario, Canada.
ORCID-Profile: Barry Rodgers-Gray
Förderung
- AstraZeneca
Zitieren
APA
Kang, J. M., Carbonell-Estrany, X., Paes, B., Rodgers-Gray, B., Fullarton, J., Tarride, J. E., Yang, H. J., Chang, Y. S., & Keary, I. (2025). Optimizing risk factors to guide COST‐effective use of palivizumab in KOREAN infants. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70021
Vancouver
Kang JM, Carbonell-Estrany X, Paes B, Rodgers-Gray B, Fullarton J, Tarride JE, et al. Optimizing risk factors to guide COST‐effective use of palivizumab in KOREAN infants. Pediatrics International. 2025;67(1). doi:10.1111/ped.70021
BibTeX
@article{Kang2025,
author = {Kang, Ji-Man and Carbonell-Estrany, Xavier and Paes, Bosco and Rodgers-Gray, Barry and Fullarton, John and Tarride, Jean-Eric and Yang, Hyeon-Jong and Chang, Yun Sil and Keary, Ian},
title = {Optimizing risk factors to guide COST‐effective use of palivizumab in KOREAN infants},
journal = {Pediatrics International},
year = {2025},
volume = {67},
number = {1},
doi = {10.1111/ped.70021}
}
EUVIMED